CervoMed is a clinical-stage biotechnology company developing neflamapimod, an orally administered small-molecule p38α inhibitor designed to treat age-related neurological disorders by targeting neuroinflammation and synaptic dysfunction. The company's lead program focuses on dementia with Lewy bodies, a common progressive dementia with no approved treatments, where early clinical trials have shown improvements in cognitive function, motor ability, and neurodegeneration biomarkers. CervoMed is pre-revenue and funds its development pipeline through a licensing agreement with Vertex Pharmaceuticals that includes milestone payments and royalties on future net sales; the company intends to commercialize neflamapimod independently or through strategic partnerships upon regulatory approval, with additional programs underway in primary progressive aphasia, stroke recovery, and amyotrophic lateral sclerosis.